1
Country: USA | Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
2
Country: USA | Funding: $798.1M
Humacyte develops novel human tissue-based investigational products for potential applications in regenerative medicine and vascular surgery. The company uses a proprietary technology platform to isolate and grow stable, “off-the shelf” investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
Humacyte develops novel human tissue-based investigational products for potential applications in regenerative medicine and vascular surgery. The company uses a proprietary technology platform to isolate and grow stable, “off-the shelf” investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
3
Country: USA | Funding: $368.4M
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
4
Country: Canada | Funding: $360.9M
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
5
Country: USA | Funding: $337.3M
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
6
Country: USA | Funding: $333.1M
Avinger designs, develops and manufactures precision medical device technology to fight Peripheral Artery Disease and help patients keep their legs.
Avinger designs, develops and manufactures precision medical device technology to fight Peripheral Artery Disease and help patients keep their legs.
7
Country: USA | Funding: $250M
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
8
Country: USA | Funding: $166.2M
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
9
Country: USA | Funding: $145.4M
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease.
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease.
10
Country: USA | Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
11
Country: USA | Funding: $98M
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
12
Country: USA | Funding: $89.9M
Profusa’s mission is to make our body’s chemistry easily accessible to improve health and wellness. We are dedicated to becoming a leader in the development of real-time biosensors that provide unprecedented insights into our overall health status.
Profusa’s mission is to make our body’s chemistry easily accessible to improve health and wellness. We are dedicated to becoming a leader in the development of real-time biosensors that provide unprecedented insights into our overall health status.
13
Country: Switzerland | Funding: $87.1M
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
14
Country: Austria | Funding: $57,5m
AFFiRiS develops first-in-class antigen specific immunotherapies for the prevention and treatment of chronic illnesses on the basis of our proprietary AFFITOME technology. We have a conviction that active immunization can play a major role in prevention and therapy of chronic civilization illnesses such as Atherosclerosis, Diabetes or Neurodegenerative Diseases.
AFFiRiS develops first-in-class antigen specific immunotherapies for the prevention and treatment of chronic illnesses on the basis of our proprietary AFFITOME technology. We have a conviction that active immunization can play a major role in prevention and therapy of chronic civilization illnesses such as Atherosclerosis, Diabetes or Neurodegenerative Diseases.
15
Country: USA | Funding: $27.8M
Underdog develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
Underdog develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
16
Country: USA | Funding: $11M
Prevencio, a life science company, is a pioneer in multi-protein in vitro diagnostic (IVD) and prognostic tests for cardiovascular disease for use in Emergency Rooms (ER), cardiology clinics, and clinical laboratories
Prevencio, a life science company, is a pioneer in multi-protein in vitro diagnostic (IVD) and prognostic tests for cardiovascular disease for use in Emergency Rooms (ER), cardiology clinics, and clinical laboratories
17
Country: USA | Funding: $30K
Flow MedTech is a Health Wildcatters portfolio company developing an innovative therapy to reduce the chance of strokes in patients with atrial fibrillation by preventing clot formation in the left atrial appendage. The aim of the company is to design, develop, and commercialize novel catheter-based devices to reduce stroke risk.
Flow MedTech is a Health Wildcatters portfolio company developing an innovative therapy to reduce the chance of strokes in patients with atrial fibrillation by preventing clot formation in the left atrial appendage. The aim of the company is to design, develop, and commercialize novel catheter-based devices to reduce stroke risk.
18
Country: USA | Funding: $300K
International Cardio Corporation develops a technology that can treat atherosclerosis in a noninvasive manner that is faster, more precise and safer for the patient.
International Cardio Corporation develops a technology that can treat atherosclerosis in a noninvasive manner that is faster, more precise and safer for the patient.
